Research and clinical progress continue in multiple therapeutic areas. AstraZeneca’s gefurulimab, a complement C5 inhibitor, demonstrated positive phase III results in generalized myasthenia gravis with significant improvements compared to placebo. Memo Therapeutics reported promising phase II results for its BK polyomavirus-neutralizing antibody, potravitug, in kidney transplant patients, with plans for phase III advancement despite missing a primary endpoint. Matchpoint Therapeutics and Novartis entered a collaboration to develop oral covalent inhibitors targeting transcription factors implicated in inflammatory diseases. Nextcure showcased preclinical data for an anti-Siglec-15 monoclonal antibody improving bone architecture in osteogenesis imperfecta models. These developments suggest ongoing expansion of treatment options for rare and immune-mediated conditions.